D.A. Gros
@dagros.bsky.social
CEO of Eledon Pharmaceuticals $ELDN. Physician passionate about pioneering medicines, patient advocacy and public health. Opinions are my own.
Thank you Drug Development & Delivery for inviting me to provide an overview of
advances in #ELDN’s research targeting the CD40L pathway to help prevent rejection in organ and islet transplantation:
drug-dev.com/drug-develop...
advances in #ELDN’s research targeting the CD40L pathway to help prevent rejection in organ and islet transplantation:
drug-dev.com/drug-develop...
DRUG DEVELOPMENT - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer
David-Alexandre C. Gros, MD, explains how researchers are targeting strategies in immunosuppression that can help donated kidneys remain healthy and viable for much longer post-transplant, thus allevi...
drug-dev.com
December 12, 2024 at 3:07 PM
Thank you Drug Development & Delivery for inviting me to provide an overview of
advances in #ELDN’s research targeting the CD40L pathway to help prevent rejection in organ and islet transplantation:
drug-dev.com/drug-develop...
advances in #ELDN’s research targeting the CD40L pathway to help prevent rejection in organ and islet transplantation:
drug-dev.com/drug-develop...
Reposted by D.A. Gros
Two Type 1 diabetes patients are potentially the 1st human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy (tegoprubart by Eledon Pharmacuticals) in clinical trial run by U Chicago Medicine Transplant Institute goodmorningamerica.com/wellness/story
goodmorningamerica.com
October 30, 2024 at 12:29 PM
Two Type 1 diabetes patients are potentially the 1st human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy (tegoprubart by Eledon Pharmacuticals) in clinical trial run by U Chicago Medicine Transplant Institute goodmorningamerica.com/wellness/story
Reposted by D.A. Gros
In this new perspective in Science, my role model and favorite immunologist Randy Noelle discusses the development of CD40L antagonists to treat autoimmunity:
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Switching off autoimmunity
Discovered 30 years ago, CD40L antagonists are proving to be powerful autoimmune drugs
www.science.org
November 22, 2024 at 11:17 PM
In this new perspective in Science, my role model and favorite immunologist Randy Noelle discusses the development of CD40L antagonists to treat autoimmunity:
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Reposted by D.A. Gros
New anti-CD40L
'AT-1501, as a monotherapy & in conjunction with other immunosuppressive agents to prevent graft rejection in NHPs. Encouragingly, AT-1501 promoted survival and function of islet and kidney allografts in cynomolgus & rhesus macaques, respectively, without evidence of thromboembolism.'
'AT-1501, as a monotherapy & in conjunction with other immunosuppressive agents to prevent graft rejection in NHPs. Encouragingly, AT-1501 promoted survival and function of islet and kidney allografts in cynomolgus & rhesus macaques, respectively, without evidence of thromboembolism.'
Science | AAAS
www.science.org
August 31, 2023 at 2:46 PM
New anti-CD40L
'AT-1501, as a monotherapy & in conjunction with other immunosuppressive agents to prevent graft rejection in NHPs. Encouragingly, AT-1501 promoted survival and function of islet and kidney allografts in cynomolgus & rhesus macaques, respectively, without evidence of thromboembolism.'
'AT-1501, as a monotherapy & in conjunction with other immunosuppressive agents to prevent graft rejection in NHPs. Encouragingly, AT-1501 promoted survival and function of islet and kidney allografts in cynomolgus & rhesus macaques, respectively, without evidence of thromboembolism.'